Trial Profile

A Randomized, Double-blind, Phase III Trial to Compare the Efficacy and Safety of AK104 Combined With Chemotherapy to Tislelizumab Combined With Chemotherapy as First-line Treatment in PD-L1 TPS < 1% Non-small Cell Lung Cancer (NSCLC)

Status: Recruiting

Phase of Trial: Phase III

Latest Information Update: 08 Mar 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Cadonilimab (Primary) ; Carboplatin; Paclitaxel; Pemetrexed; Tislelizumab
Indications Non-small cell lung cancer; Squamous cell cancer
Focus Registrational; Therapeutic Use
Sponsors Akeso Biopharma

06 Mar 2024 According to an Akeso Biopharma media release, the company announced the first patient has been enrolled and dosed in this trial.
06 Mar 2024 Status changed from not yet recruiting to recruiting, according to an Akeso Biopharma media release.
18 Aug 2023 New trial record

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com